Stayble Therapeutics publishes interim report for the first quarterMay 2022 Regulatorisk
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes the interim report for the first quarter of 2022. The interim report is available as an attached document and on the Company’s website.
Highlights during the first quarter (January – March 2022)
- Stayble comments on the Company's ongoing Phase IIb clinical trial, which is ongoing in for example Russia. The Company is closely monitoring the progress and believes that the study can continue without risk to patient safety, quality or conduct. This means that the Company continues to follow the previously communicated timetable.
- Stayble announces that the Company is changing its Certified Adviser to Svensk Kapitalmarknadsgranskning AB starting 1 April 2022.
Highlights after the end of the period
- Stayble announces that the Company has enrolled 75% of all patients in the ongoing Phase IIb clinical trial. Multiple efforts to increase patient enrollment in addition to the reduced impact of the Covid-19 pandemic have resulted in a significant increase in enrollment rates. The enrolment rate is in line with the set timetable and the final target to enroll all patients during the year.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail firstname.lastname@example.org